Freenome Launches SimpleScreen Lung Cancer Blood Test
The new blood-based screening test is designed for adults aged 50 to 80 with a 20 pack-year smoking history.
Updated on Oct. 20, 2026 in Cancer
Live Poll
Would you trust a blood-based test for early cancer detection over traditional screening methods?
Freenome has launched its SimpleScreen Lung blood test to provide a new screening option for high-risk adults. Providers can now order the test alongside the company's FDA-approved SimpleScreen CRC test for a single blood draw.
Why it matters
Low screening rates currently hinder early detection, with fewer than 20% of eligible individuals up to date on lung cancer screening. This combined testing approach aims to simplify the process for patients who also require colorectal cancer screening.
SimpleScreen Lung demonstrated 85% sensitivity and 50% specificity in an independent cohort with a 99.8% negative predictive value. The test is indicated for adults aged 50 to 80 who have a 20 pack-year smoking history.
The players
Freenome
Freenome is a biotechnology company based in Brisbane, California, that specializes in developing early cancer detection screening tools.
Abbott
Abbott is a global medical device and healthcare company that holds exclusive U.S. commercial rights to the SimpleScreen CRC test.
The details
The test detects lung cancer signals through cell-free DNA from a single blood draw, which can be performed simultaneously with the colorectal cancer screening. Nearly 40% of adults eligible for colorectal screening are not currently up to date, highlighting the need for more accessible options.
Timeline
2023: The American Cancer Society updated its lung cancer screening guidelines.
June 2, 2025: Clinical validation of the PREEMPT CRC study was published.
October 20, 2026: Freenome officially announced the launch of the SimpleScreen Lung test.
October 20 to 24, 2026: Freenome presents its screening portfolio at the FMX conference in Nashville.
The Big Picture
The introduction of this test follows the framework established by the American Cancer Society's 2023 lung cancer screening guidelines. This launch represents a broader industry shift toward integrating multiple cancer screenings into routine blood-based diagnostics.
Patients who meet the smoking history requirements can now potentially complete two essential cancer screenings with a single blood draw at their provider's office. This reduces the number of separate medical appointments needed for individuals to stay up to date on recommended screenings.
The takeaway
Early detection remains the most effective way to improve outcomes for high-risk patients. Individuals should consult with their healthcare providers to determine if these new blood-based screening tests are appropriate for their specific health history.
Further reading
For more information on current diagnostic trends, visit the United States Cancer section.
Live Poll
Would you trust a blood-based test for early cancer detection over traditional screening methods?
